Ratio detection kit for circulating tumor cells and preparation method and application thereof
By constructing a ratiometric SERS detection kit and utilizing DNA walker to assist in the formation of networked nanostructures, the sensitivity and anti-interference issues in CTC detection were resolved, achieving highly sensitive and specific quantitative detection of circulating tumor cells.
Patent Information
- Application Number
- CN202210605940.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-05-31
AI Technical Summary
Existing technologies have low sensitivity in detecting circulating tumor cells (CTCs), and SERS technology has poor resistance to interference from impurities in low-purity detection systems, which cannot meet the reliable detection requirements of rare CTCs in blood.
A ratiometric SERS detection kit based on aptamer targeting of CTCs and triggering DNA walker-assisted formation of Walker probe-SERS probe network nanostructures was designed. The kit includes Walker probes, SERS probes, and an auxiliary DNAzyme for specific cleavage of substrate nucleic acid chains. The nucleic acid chains are modified by Au-S covalent bonds and the network nanostructures are formed by Zn2+ cleavage for detection.
It achieves highly sensitive quantitative detection of CTCs, with a detection limit of 1 cell/mL. It has good specificity and can reliably distinguish non-specific cells in complex blood backgrounds, making it suitable for reliable detection and early diagnosis of CTCs.
Smart Images

Figure CN114942223B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of functional nano materials and biological detection, and specifically relates to a ratio detection kit for circulating tumor cells and a preparation method and application thereof. Background Art
[0002] The current incidence, metastasis and mortality of cancer are still high. However, the traditional tissue biopsy evaluation, which is rated as the "gold standard" for tumor diagnosis, is usually based on medical imaging and other technologies to implement tumor detection. It has great difficulties and risks in obtaining multiple and continuous tissues. In addition, tumors will evolve and become heterogeneous during treatment and development. This makes the evaluation of primary tumor tissue by tissue biopsy not represent the real-time status of molecular markers, nor the overall genomic status of tumors. By performing minimally invasive liquid biopsies on biological fluids such as blood, saliva and urine, multiple and continuous samples can be obtained to achieve overall or dynamic monitoring of cancer progression and treatment response, providing a good opportunity for personalized cancer treatment. At present, markers such as circulating tumor cells (CTCs), free circulating nucleic acids (cfDNAs), proteins and exosomes (EVs) are widely used in liquid biopsies. Among them, CTCs shed from primary tumor tissues retain the molecular characteristics of the original tumor tissues. Detection and analysis of CTCs that survive in peripheral blood can help to monitor the course of patients in real time and dynamically, which is of great significance for the diagnosis and treatment, drug evaluation and prognosis detection of cancer patients. In the patient's blood, the abundance of CTCs is extremely low, about 10 in one milliliter of whole blood sample. 9 -10 10 red blood cells and 10 6 -10 7 White blood cells are present in the blood, while CTCs are only a few. The same type of tumor has different protein expression levels on the surface of cancer cells in different patients. In addition, during the metastasis process, some CTCs will undergo epithelial-mesenchymal transition (EMT), resulting in a decrease in epithelial characteristics on the cell surface and an increase in mesenchymal phenotypic characteristics. These characteristics make CTCs, which exist in trace amounts in the blood, highly dependent on the targeted molecules used in the detection method during the detection process. Therefore, the development of detection technology with reliable recognition and ultra-sensitive analysis is very necessary to improve the sensitivity and specificity of CTCs determination.
[0003] In recent years, nucleic acid aptamers, also known as "chemical antibodies", have been widely used in the analysis of low-abundance substances to be detected because they can effectively improve the efficiency and accuracy of targeted binding, have good programmability in molecular structure and designability of nucleic acid sequences, and are easy to combine with nucleic acid-based signal amplification technology. As an ultra-sensitive non-destructive analytical technology, SERS has good resistance to photobleaching and photodegradation, and its detection sensitivity can even reach the single-molecule level. Relevant studies in recent years have also shown that this technology has excellent sensitivity in CTCs detection. However, SERS technology still faces two problems in the application of CTCs detection: on the one hand, the content of CTCs in blood samples collected clinically is relatively low, and the low concentration of the substance to be detected makes the detection sensitivity unable to meet the detection requirements; on the other hand, the exponential signal enhancement characteristics of SERS technology make it poor in the detection of low-purity complex samples. The error of the sensor itself and the slight fluctuation of the detection conditions will cause a large deviation in the detection results. The ratiometric SERS sensor can avoid the influence of external condition fluctuations on the SERS intensity to a certain extent, thereby improving the stability and reliability of the SERS signal output.
[0004] The Chinese patent application number 201910807092.7 discloses a "tumor cell marker miRNA-21 and tumor cell detection system", which combines 3D DNA Walker nanomachine amplification and DNA tetrahedron nanoprobes to perform ratiometric and dual-mode detection of tumor cells and tumor cell marker miRNA-21. However, this method only quantitatively detects the tumor cell marker miRNA-21 in vitro, and uses Raman and fluorescence imaging to characterize the presence of tumor marker miRNA-21 in cancer cells HeLa. It has the ability to visually detect tumor cells, but cannot reflect the number of CTCs in the sample to be detected by the content of miRNA-21. For circulating tumor cells that have fallen off from solid tumor tissues and retained the integrity of tumor cells, it is more suitable for protein localization and cell morphology research of tumor cells than those derived from cell-free DNA. Its quantity has important guiding significance for the examination of tumor metastasis, the prediction of patient prognosis, and the monitoring of cancer treatment results. In addition, the signal molecules used in this method are all labeled at the ends of DNA, and reducing the labeling of signal molecules at the ends of DNA can effectively reduce the cost of the detection kit. In order to solve the above technical problems, the present invention constructs an ultra-sensitive and non-destructive ratiometric SERS sensing technology to achieve ratiometric SERS quantitative detection of CTCs, which can meet the requirements for reliable detection and counting of rare CTCs in blood. Summary of the invention
[0005] In view of the great demand for rapid and sensitive determination of circulating tumor cells (CTCs) in current tumor molecular detection, in order to overcome the shortcomings of low sensitivity in low-abundance CTCs detection and poor anti-impurity interference performance of SERS technology in low-purity detection systems, the present invention studies and designs a strategy based on aptamer targeting CTCs and triggering DNA walker to assist in forming a Walker probe-SERS probe networked nanostructure, and provides a ratiometric surface enhanced Raman scattering (SERS) detection kit for circulating tumor cell detection and a preparation method and application thereof. The ratiometric SERS detection kit is easy to prepare, does not require amplification and professional technicians to operate, has high sensitivity (detection limit reaches 1 cell / mL), good specificity (can clearly distinguish nonspecific cells, and has a reliable recovery rate in a complex blood background), and has outstanding application advantages in the field of CTCs detection.
[0006] The purpose of the present invention is to be achieved through the following technical solutions:
[0007] A ratiometric detection kit for circulating tumor cells, comprising a first reagent, a second reagent and a third reagent;
[0008] The first reagent is a Walker probe, which is prepared by modifying the surface of magnetic core gold shell nanoparticles with walking nucleic acid chains, hairpin nucleic acid chains H1 containing enzyme response substrates, and thiol polyethylene glycol methoxy SH-PEG-OMe; the walking nucleic acid chain is a nucleic acid aptamer chain SYL3C-ROX and Zn 2+ Hybridized by specific DNAzyme chains;
[0009] The second reagent is a SERS probe, which is prepared by modifying the surface of gold nanoparticles with a hairpin-type nucleic acid chain H2 and a Raman signal molecule 5,5'-dithiobis(2-nitrobenzoic acid);
[0010] The third reagent is a zinc sulfate solution that assists DNAzyme in specifically cutting the substrate nucleic acid chain.
[0011] Furthermore, the nucleic acid aptamer chains SYL3C-ROX, Zn 2+ The base sequences of the specific DNAzyme chain and the hairpin nucleic acid chain H1 are shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, respectively.
[0012] Furthermore, the base sequence of the hairpin nucleic acid chain H2 is shown in SEQ ID NO.4.
[0013] Furthermore, the particle size of the magnetic core gold shell nanoparticles is 100-300 nm; the particle size of the gold nanoparticles is 15-100 nm.
[0014] The method for preparing the ratiometric detection kit for circulating tumor cells as described above comprises the following steps:
[0015] (I) Preparation of the first reagent, Walker probe:
[0016] 1) The aptamer chain SYL3C-ROX was combined with Zn 2+ The specific DNAzyme chain is mixed to prepare a walking nucleic acid chain with a double-stranded structure in which the enzyme chain part is protected by the nucleic acid aptamer, and after cooling to room temperature, the walking nucleic acid chain is mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100-1:1000 and reacted at room temperature for 4 hours;
[0017] 2) After annealing the hairpin nucleic acid chain H1, it was mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100 to 1:1000 and allowed to react at room temperature for 4 h;
[0018] 3) Add 600 μL of the walking nucleic acid chain obtained in step 1) and 600 μL of the hairpin nucleic acid chain H1 obtained in step 2) at a molar ratio of 1:5-1:10 to 18 mL of magnetic core-gold shell nanoparticles to form a mixture, and react at room temperature overnight;
[0019] 4) Add 28 mM thiol polyethylene glycol methoxy SH-PEG-OMe and magnetic core gold shell nanoparticles in a volume ratio of 1:100-1:1000 to the mixture prepared in step 3), react at room temperature for 10 min, centrifuge at 2000 rpm for 10 min for washing, and finally disperse the product in PBS buffer to prepare the Walker probe;
[0020] (II) Preparation of the Second Reagent, i.e., SERS Probe
[0021] 1) After the hairpin nucleic acid chain H2 is annealed, it is mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100 to 1:1000 and reacted at room temperature for 4 hours;
[0022] 2) 10 μM hairpin nucleic acid chain H2 and gold nanoparticles were mixed at a volume ratio of 1:5-1:10 at room temperature overnight, and then 2 M NaCl was added in small amounts several times within 4 hours to age the probe;
[0023] 3) 100 μM Raman signal molecule 5,5'-dithiobis(2-nitrobenzoic acid) and gold nanoparticles were added to the mixture obtained by the reaction in step 2) at a volume ratio of 1:10-1:20, and reacted for 3 hours;
[0024] 4) Remove the supernatant by centrifugation, and disperse the centrifugal sediment with PBS solution to obtain the SERS probe;
[0025] (III) Preparation of the third reagent: Dissolve zinc sulfate heptahydrate in ultrapure water to prepare a zinc sulfate solution that assists DNAzyme in specifically cleaving the substrate nucleic acid chain.
[0026] A non-diagnostic application of the ratiometric SERS detection kit for circulating tumor cell detection as described above in the detection of breast cancer circulating tumor cells MCF-7, the application steps comprising:
[0027] 1) Add MCF-7 cells to PBS buffer to obtain a sample solution for later use; wherein the concentration of MCF-7 cells in the obtained sample solution ranges from 5 to 1000 cells / mL;
[0028] 2) mixing the first reagent, the second reagent, the third reagent and a sample solution containing different numbers of MCF-7 cells to be detected;
[0029] 3) The mixed sample obtained in step 2) was magnetically separated and washed several times with PBS buffer and then subjected to SERS testing. The SERS spectra of different numbers of MCF-7 cells to be tested were detected, and 5,5'-dithiobis(2-nitrobenzoic acid), i.e., DTNB, was obtained at 1331 cm -1 Characteristic peak signal intensity I 1331 and ROX at 1500 cm -1 Characteristic peak signal intensity I 1500 The ratio I R (I R =I 1331 / I 1500 ), according to the working curve of the SERS detection kit, the detection limit of the SERS detection kit for detecting MCF-7 cells (S / N=3) was calculated.
[0030] Furthermore, the co-culture condition in step 3) is culturing in a constant temperature mixer at 37° C. and 300 rpm for 60 minutes.
[0031] Furthermore, the applying step also includes:
[0032] MCF-7 cells were added to the peripheral blood extraction sample to obtain a sample solution for standby use, wherein the concentration range of MCF-7 cells in the obtained sample solution was 75-600 cells / mL; the first reagent, the second reagent, and the third reagent were mixed with the sample solution containing different numbers of MCF-7 cells to be detected; the mixed sample obtained by the above treatment was magnetically separated and washed for multiple times with PBS buffer, and then a SERS test was performed to obtain a SERS spectrum, and a DTNB at 1331 cm -1 Characteristic peak signal intensity I 1331 and ROX at 1500 cm -1 Characteristic peak signal intensity I 1500 The ratio I R (I R =I 1331 / I 1500 ), and the concentration of circulating tumor cells in the sample was calculated based on the working curve of the SERS detection kit.
[0033] Furthermore, the base sequence of the nucleic acid aptamer SYL3C-ROX chain is shown in SEQ ID NO.1, and the Zn 2+ The base sequence of the specific DNAzyme chain is shown as SEQ ID NO.2, the base sequence of the hairpin nucleic acid chain H1 is shown as SEQ ID NO.3, and the base sequence of the hairpin nucleic acid chain H2 is shown as SEQ ID NO.4.
[0034] Furthermore, in the step 2), the first reagent, the second reagent and the third reagent are mixed with a sample solution containing different numbers of MCF-7 cells to be detected at a volume ratio of 1:0.2:1 to 1:2:1.
[0035] Reaction principle (taking the detection of breast cancer cells MCF-7 as an example): The walking chain and hairpin nucleic acid chain H1 formed by annealing the nucleic acid aptamer chain SYL3C-ROX and the DNAzyme chain are modified to the magnetic core gold shell nanoparticles GMNPs through Au-S covalent bonds, and the surface is modified with thiol polyethylene glycol methoxy SH-PEG-OMe to prepare the first reagent (Walker probe); the hairpin nucleic acid chain H2 and DTNB are fixed on the surface of Au NPs in sequence to prepare the second reagent (SERS probe); zinc sulfate heptahydrate is dissolved in ultrapure water to prepare the third reagent (ZnSO4).
[0036] In the presence of target MCF-7 cells, the nucleic acid aptamer chain SYL3C-ROX on the walking chain in the first reagent binds to the cell surface protein, resulting in the release of the DNAzyme chain. 2+The hairpin nucleic acid chain H1 is sheared, and the H1 fragment remaining on the surface of GMNPs after shearing can hybridize with H2 on the second reagent SERS probe, thereby forming a networked nanostructure of Walker probe-SERS probe containing rich SERS hotspots. At the same time, the sheared DNAzyme is released for recycling. Finally, by testing the Raman signal of the networked nanostructure of Walker probe-SERS probe, rapid, specific and highly sensitive detection of circulating tumor cells MCF-7 can be achieved. On the contrary, in the absence of MCF-7, the mixture of the first reagent and the second reagent cannot form a nanoparticle network aggregate. The product obtained after magnetic separation only has a single first reagent Walker probe, and in the Raman detection results, there is only a relatively obvious ROX molecule signal, while the DTNB molecule in the second reagent has no obvious signal output. By analyzing the ratio of DTNB and ROX signals in the networked nanostructure of Walker probe-SERS probe, the ratio SERS signal I can be obtained. R (I R =I 1331 / I 1500 ) and the relationship between the number of cells, construct I R Linear working curve with cell number (S / N=3).
[0037] The beneficial effects of the present invention are:
[0038] The present invention provides a ratiometric detection kit for circulating tumor cells and a preparation method and application thereof. The SERS kit comprises a first reagent, a second reagent and a third reagent. The first reagent is a Walker probe, which is modified with nucleic acid aptamers SYL3C-ROX and Zn 2+ The invention discloses a ratiometric surface enhanced Raman scattering (SERS) detection kit for circulating tumor cell detection, which is simple to prepare, does not require amplification and professional technicians to operate, has high sensitivity (detection limit reaches 1 cell / mL level), good specificity (can clearly distinguish nonspecific cells, and has a reliable recovery rate in complex blood background), can realize ratiometric SERS quantitative detection of CTCs, meets the requirements of reliable detection and counting of rare CTCs in blood, and has outstanding application advantages in the fields of CTCs detection and early diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 Schematic diagram of a method for preparing a ratiometric SERS detection kit for circulating tumor cell detection according to the present invention;
[0040] Figure 2a The gel electrophoresis characterization of the DNA hybridization process involved in the ratiometric SERS detection kit described in Example 2 of the present invention;
[0041] Figure 2b The absorption spectrum characterization of the feasibility of the target MCF-7 involved in Example 2 of the present invention triggering the DNA walker to assist in forming the Walker probe-SERS probe network-like plasma nanostructure;
[0042] Figure 2c Dynamic light scattering characterization of the feasibility of the target MCF-7 involved in Example 2 of the present invention triggering the DNA walker to assist in forming a Walker probe-SERS probe network-like plasma nanostructure;
[0043] Figure 2d Raman characterization of the feasibility of the target MCF-7 involved in Example 2 of the present invention triggering the DNA walker to assist in forming a Walker probe-SERS probe network-like plasma nanostructure;
[0044] Figure 2e TEM characterization of the Walker probe-SERS probe network structure induced by MCF-7 involved in Example 2 of the present invention
[0045] Figure 3a The SERS spectra corresponding to different concentrations of MCF-7 detected by the ratiometric SERS detection kit described in Example 3 of the present invention;
[0046] Figure 3b The ratiometric SERS detection kit described in Example 3 of the present invention detects the DTNB at 1331 cm in each spectral line of the SERS spectra corresponding to different concentrations of MCF-7. -1 The characteristic peak signal intensity and ROX at 1500 cm -1 The ratio of characteristic peak signal intensity I R (I R =I 1331 / I 1500 ) and the linear working curve of cell number;
[0047] Figure 4a The SERS spectra corresponding to different types of cells detected by the ratiometric SERS detection kit described in Example 4 of the present invention;
[0048] Figure 4bThe ratiometric SERS detection kit described in Example 4 of the present invention detects the DTNB at 1331 cm in each spectral line of the SERS spectra corresponding to different types of cells. -1 The characteristic peak signal intensity and ROX at 1500 cm -1 The ratio of characteristic peak signal intensity I R (I R =I 1331 / I 1500 );
[0049] Figure 5 This is a SERS spectrum diagram corresponding to the detection of MCF-7 cells of different concentrations in a blood sample by the ratiometric SERS detection kit described in Example 5 of the present invention.
[0050] Description of Sequence Listing
[0051] SEQ ID NO.1: base sequence of nucleic acid aptamer chain SYL3C-ROX;
[0052] SEQ ID NO.2: Zn 2+ The base sequence of the specific DNAzyme chain;
[0053] SEQ ID NO.3: base sequence of hairpin nucleic acid chain H1;
[0054] SEQ ID NO.4: Base sequence of hairpin nucleic acid chain H2. DETAILED DESCRIPTION
[0055] In order to help those skilled in the art better understand the content of the present invention, an embodiment of the present invention is described in detail below. This embodiment is implemented based on the technical solution of the present invention, and a detailed implementation method and specific operation process are given. However, the content of the present invention is not limited to the following examples.
[0056] The nucleic acid aptamer chains SYL3C-ROX, Zn 2+ The specific DNAzyme chain, the hairpin nucleic acid chain H1 and the hairpin nucleic acid chain H2 are as follows:
[0057] SYL3C-ROX: 5'-ROX-CAC TAC AGA GGT TGC GTC TGT CCC ACG TTG TCA TGG GGGGTT GGC CTG-3'
[0058] DNAzyme: 5'-SH-(CH2)6-TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTTTTT TTT TTT TTT TTG ACG ATC TAG TTG AGC TGT CAG ACG CAA CCT CTG TAG TG-3'
[0059] H1:5'-SH-(CH2)6-TTT TTT ATA ACG ACG ATT GAA ATA GTC TGA CGT TGA AGGATC GTC TTA GCA GGC GCG TCG TTA T-3'
[0060] H2: 5'-SH-(CH2)6-TTT TTT TCA ACG TCA GAC TAT TTC AAT CGT CGT TAT TTTTTT TTA CGA TTG AAA TAG TCT GAC GTT GA-3'.
[0061] Taking the detection of breast cancer cells MCF-7 as an example, the DNA base sequence fragments used in the present invention are all artificially synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0062] Example 1: Preparation of a ratiometric detection kit for circulating tumor cells
[0063] 1. Preparation of the first reagent, Walker probe:
[0064] (1) The aptamer chain SYL3C-ROX is combined with Zn 2+ The specific DNAzyme chains were mixed and reacted at 95°C for 5 minutes to prepare a double-stranded walking chain in which part of the enzyme chain structure was protected by the nucleic acid aptamer. After it was cooled to room temperature, the walking chain was mixed with TCEP solution (i.e., tricarboxyethylphosphine solution) at a molar ratio of 1:100 to 1:1000 and reacted at room temperature for 4 hours.
[0065] (2) After annealing the hairpin nucleic acid chain H1 (heating at 95°C for 5 minutes and then cooling to room temperature), it is mixed with TCEP solution at a molar ratio of 1:100 to 1:1000 and allowed to react at room temperature for 4 hours.
[0066] (3) Add 600 μL of the walking strand obtained in step (1) and 600 μL of the hairpin nucleic acid strand H1 in step (2) to 18 mL of GMNPs at a molar ratio of 1:5 to 1:10 to form a mixture and react at room temperature overnight.
[0067] (4) To the mixture prepared in step (3), add 28 mM thiol polyethylene glycol methoxy SH-PEG-OMe and magnetic core gold shell nanoparticles in a volume ratio of 1:100 to 1:1000, react at room temperature for 10 min, centrifuge at 2000 rpm for 10 min to wash, and finally disperse the product in 1.8 mL PBS to prepare the Walker probe.
[0068] 2. Preparation of the second reagent, namely the SERS probe:
[0069] (1) After the hairpin nucleic acid chain H2 is annealed, the hairpin nucleic acid chain H2 is mixed with a TCEP solution at a molar ratio of 1:100 to 1:1000 and allowed to react at room temperature for 4 h;
[0070] (2) 10 μM hairpin nucleic acid chain H2 and gold nanoparticles were mixed at a volume ratio of 1:5-1:10 at room temperature overnight, and then 2 M NaCl was added in small amounts several times within 4 h to age the probe;
[0071] (3) Add 100 μM Raman signal molecule DTNB and gold nanoparticles at a volume ratio of 1:10 to 1:20 to the mixture obtained in step (2) above, and react for 3 hours;
[0072] (4) Finally, the supernatant was removed by centrifugation and the centrifuged sediment was dispersed with PBS solution to obtain the SERS probe.
[0073] 3. Preparation of the third reagent: Dissolve zinc sulfate heptahydrate in ultrapure water to prepare a zinc sulfate solution that assists DNAzyme in specifically cleaving the substrate nucleic acid chain.
[0074] Example 2: Feasibility characterization of ratiometric SERS detection kit
[0075] The non-diagnostic applications of the above-mentioned ratiometric detection kit for circulating tumor cells are as follows (taking the detection of breast cancer cells MCF-7 as an example):
[0076] A certain concentration of circulating tumor cells MCF-7 was added to 900 μL PBS buffer to obtain a sample solution for later use; 50 μL of the first reagent, 50 μL of the second reagent, and 5 μL of the third reagent were mixed with a certain concentration of the sample solution of the cells to be tested MCF-7; no MCF-7 cells, no third reagent, and no mixture of MCF-7 cells and the third reagent were used as blank controls. The culture time was 60 minutes in a constant temperature mixer at 37°C and 300 rpm. The treated mixed sample was magnetically separated and washed several times with PBS buffer, dispersed in 50 μL PBS, enriched with an external magnetic field, and air-dried for SERS testing.
[0077] The feasibility of DNA hybridization of the target MCF-7 to trigger the DNA walker to assist in the formation of Walker probe-SERS probe network-like plasmonic nanostructures was characterized by 10% polyacrylamide gel electrophoresis. Figure 2a As shown, lanes 1 and 2 are SYL3C and DNAzyme, respectively. The migration speed of the new band in lane 3 is significantly lower than that of the two single-stranded DNAs, which belongs to the hybridization product of SYL3C and DNAzyme (i.e., the walking strand). Lane 4 is the mixture of SYL3C, DNAzyme and H1 with Zn added. 2+ The brightness of the band of H1 in lane 1 is basically the same as that of H1 alone in lane 6, indicating that in the absence of target cells, the DNAzyme is blocked by the aptamer, even with the addition of Zn 2+ Lane 5 is the hybrid product of DNAzyme and H1 with Zn added. 2+ This lane simulates the presence of target cells, where the aptamer chain is captured and the exposed DNAzyme is exposed in Zn 2+ The newly appeared band in the lower middle lane proves that DNAzyme can cut H1 under the action of Zn 2+ The substrate H1 can be catalyzed and cleaved with the assistance of. Lane 8 is a mixed solution of H1 and H2. Compared with the individual H1 bands (lane 6) and H2 bands (lane 7), the overlap of the bands can be clearly observed from the corresponding position of this lane. This is because the number of bases of H1 and H2 is relatively close. The appearance of a lighter band above the lane indicates that only a small amount of H1 and H2 hybridize, indicating that the complete H1 and H2 present a relatively stable hairpin structure and are not easy to hybridize. Lane 9 is a mixture of DNAzyme, H1 and H2 with Zn added 2+ , which is used to simulate the presence of target cells, when the aptamer chain is captured and the products after the cleavage are initiated. Compared with lane 5, lane 9 has an obvious band with a slower migration speed, indicating that the remaining fragments after H1 cleavage can successfully hybridize with H2. Lane 10 is a mixture of SYL3C, DNAzyme, H1 and H2 with the addition of Zn 2+ , that is, when the target cells are not present, the DNAzyme is blocked by the aptamer, even if Zn 2+ It was also unable to start working, and no new band appeared in lane 10, which was consistent with expectations, indicating that the designed working mechanism had good specificity.
[0078] Further absorption spectroscopy ( Figure 2b )、Dynamic Light Scattering( Figure 2c ), Raman ( Figure 2d ), and TEM ( Figure 2e) et al. characterized the feasibility of the target MCF-7 triggering DNA walker to assist in the formation of Walker probe-SERS probe network-like plasma nanostructures. EpCAM-positive MCF-7 cells were selected as the CTCs model to be detected. Here, the reaction system was set to contain only Walker probe and SERS probe (1#), Walker probe, SERS probe and Zn 2+ (2#), three blank controls of Walker probe, SERS probe and MCF-7 cells (3#), and the reaction system containing Walker probe, SERS probe, Zn 2+ and MCF-7 cell (4#) experimental group. Comparing the absorption peak, hydrated particle size and Raman spectrum results of the four experimental groups, it can be clearly observed that when Walker probe, SERS probe, and Zn 2+ When the MCF-7 cells were added, the absorption peak of the system shifted significantly to 728 nm, the hydrated particle size increased to 880.2 nm, and the DTNB peak at 1331 cm appeared in the SERS spectrum. -1 and ROX at 1500 cm -1 and 1646 cm -1 The characteristic peaks at 100 nm and 10 nm respectively were observed, and the obvious nanoparticle assembly phenomenon was observed after TEM characterization of the product. The above results show that the designed CTCs-targeted specific triggered network-like plasma nanostructure can be used for the detection of target CTCs.
[0079] Example 3: Working curve and detection limit of ratiometric SERS detection kit for MCF-7
[0080] 50 μL of the first reagent, 50 μL of the second reagent, 5 μL of the third reagent and 900 μL of PBS containing different concentrations of the MCF-7 cells to be detected (5-1000 cells / mL) were mixed, and after incubation in a constant temperature mixer at 37℃ and 300 rpm for 60 minutes, the samples were magnetically separated and washed several times with PBS buffer. After the products were enriched and air-dried with an external magnetic field, SESR tests were performed (Raman test conditions: scanning time 1s, laser power 10%, objective magnification 20x, cumulative times 10 times, excitation light wavelength 633 nm), and the SERS spectrum and its characteristic signal intensity value were obtained. The working curve was made with the concentration of the MCF-7 cells to be detected as the horizontal axis and the characteristic peak intensity value of the SERS probe as the vertical axis. The detection limit of the SERS detection kit for detecting MCF-7 was calculated based on the working curve. Figure 3a The SERS spectra obtained by detecting MCF-7 cells with different concentrations are shown in Figure 2. Figure 3b The spectral lines of the DTNB at 1331 cm -1 The characteristic peak signal intensity and ROX at 1500 cm-1 The ratio SERS signal I is obtained by analyzing the characteristic peak signal intensity. R (I R =I 1331 / I 1500 ). For the detection of MCF-7, the working curve is I R =6.97×10 -3 C MCF-7 +0.486( R 2 =0.945), and the detection limit was calculated to be 1 cell / mL.
[0081] Example 4: Characterization of the specificity of ratiometric SERS detection kit for detecting MCF-7
[0082] MCF-7 was selected as the positive control, HeLa, LO2, HUVEC, Hs578Bst and other cells were selected as negative controls, and the reaction buffer without any additional biomolecules was used as a blank control. Take 50 μL of the first reagent, 50 μL of the second reagent, and 5 μL of the third reagent and mix them with 900 μL PBS containing different types of cell sample solutions to be tested. After the mixed solution was incubated in a constant temperature mixer at 37℃ and 300 rpm for 60 minutes, it was magnetically separated and washed multiple times with PBS buffer. After the product was enriched and air-dried with an external magnetic field, the SESR test was performed to obtain the SERS spectrum and its characteristic peak intensity value. Figure 4a It is to detect the SERS spectra of different biomolecule samples. Figure 4b The spectral lines are at 1331 cm in DTNB -1 The characteristic peak signal intensity and ROX at 1500 cm -1 The ratio SERS signal I is obtained by analyzing the characteristic peak signal intensity. R (I R =I 1331 / I 1500 ).from Figure 4b It can be clearly observed from the statistical results that the ratio SERS signal I obtained by the nonspecific cell experimental group R Similar to the blank sample, it is much lower than the signal of the target cell MCF-7 to be detected, which shows that the ratiometric SERS detection kit has good specificity and reliability.
[0083] Example 5: Characterization of the recovery rate of MCF-7 detected by SERS detection kit
[0084] Take 4 mL of healthy human peripheral blood sample, add it into a centrifuge tube containing 2 mL of Histopaque-1119 and 2 mL of Histopaque-1077 lymphocyte separation medium, centrifuge at 700 g for 30 min at room temperature, take out the separated mononuclear cells (leukocytes and) and disperse them in PBS, then centrifuge at 200 g for 10 min and resuspend the cells in 4 mL of PBS. 6 In the background of leukocytes, 50 μL of the first reagent, 50 μL of the second reagent, 5 μL of the third reagent and 900 μL of PBS containing different concentrations of MCF-7 cells to be detected (75~600 cells / mL) were mixed, incubated in a constant temperature mixer at 37℃ 300 rpm for 60 minutes, and then magnetically separated and washed multiple times with PBS buffer. The product was enriched and air-dried with an external magnetic field, and then the SESR test was performed. The concentration of CTCs in peripheral blood samples was calculated by the standard curve. The recovery rate of MCF-7 was detected by the ratiometric SERS detection kit. The experimental results are shown in Figure 5 As shown, it is proved that the ratiometric SERS detection kit designed in the present invention has good accuracy; Table 1 shows the SERS spectra of DTNB at 1331 cm in each spectral line corresponding to the SERS spectra of MCF-7 cells with different concentrations detected by the SERS detection kit. -1 Characteristic peak signal intensity and ROX at 1500cm -1 The ratio of characteristic peak signal intensity I R (I R =I 1331 / I 1500 )The recovery rate was calculated.
[0085] Table 1
[0086] Sample No. Number of cells added Number of cells detected Recovery rate / % Relative standard deviation / % 1 75 78.4 104.5 6.8 2 150 148.3 98.9 4.6 3 300 308.4 102.8 7.0 4 600 564.1 94.0 4.7
[0087] The above description is only a preferred embodiment of the present invention and is not limited to the above implementation mode. Any equivalent modifications, equivalent substitutions and improvements made by ordinary technicians in this field based on the contents disclosed by the present invention should be included in the protection scope recorded in the claims. Sequence Listing <110> Nanjing University of Posts and Telecommunications <120> Ratio detection kit for circulating tumor cells and preparation method and application thereof <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 48 <212> DNA <213> Artificial Sequence <400> 1 cactacagag gttgcgtctg tcccacgttg tcatgggggg ttggcctg 48 <210> 2 <211> 89 <212> DNA <213> Artificial Sequence <400> 2 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt gacgatctag 60 ttgagctgtc agacgcaacc tctgtagtg 89 <210> 3 <211> 64 <212> DNA <213> Artificial Sequence <400> 3 ttttttataa cgacgattga aatagtctga cgttgaagga tcgtcttagc aggcgcgtcg 60 ttat 64 <210> 4 <211> 68 <212> DNA <213> Artificial Sequence <400> 4 tttttttcaa cgtcagacta tttcaatcgt cgttattttt ttttacgatt gaaatagtct 60 gacgttga 68
Claims
1. A ratiometric detection kit for circulating tumor cells, characterized in that: The detection kit comprises a first reagent, a second reagent and a third reagent; The first reagent is a Walker probe, which is prepared by modifying the surface of magnetic core gold shell nanoparticles with walking nucleic acid chains, hairpin nucleic acid chains H1 containing enzyme response substrates, and thiol polyethylene glycol methoxy SH-PEG-OMe; the walking nucleic acid chain is a nucleic acid aptamer chain SYL3C-ROX and Zn 2+ The specific DNAzyme chain is hybridized; the nucleic acid aptamer chain SYL3C-ROX, Zn 2+ The base sequences of the specific DNAzyme chain and the hairpin nucleic acid chain H1 are shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3 respectively; The second reagent is a SERS probe, which is prepared by modifying the surface of gold nanoparticles with a hairpin nucleic acid chain H2 and a Raman signal molecule 5,5'-dithiobis(2-nitrobenzoic acid); the base sequence of the hairpin nucleic acid chain H2 is shown in SEQ ID NO.4; The third reagent is a zinc sulfate solution that assists DNAzyme in specifically cutting the substrate nucleic acid chain.
2. The ratiometric detection kit for circulating tumor cells according to claim 1, characterized in that: The particle size of the magnetic core gold shell nanoparticles is 100-300 nm; the particle size of the gold nanoparticles is 15-100 nm.
3. The method for preparing the ratiometric detection kit for circulating tumor cells according to claim 2, characterized in that: The following steps are involved: (I) Preparation of the first reagent, Walker probe: 1) The aptamer chain SYL3C-ROX was combined with Zn 2+ The specific DNAzyme chain is mixed to prepare a walking nucleic acid chain with a double-stranded structure in which the enzyme chain part is protected by the nucleic acid aptamer, and after cooling to room temperature, the walking nucleic acid chain is mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100-1:1000 and reacted at room temperature for 4 hours; 2) After annealing the hairpin nucleic acid chain H1, it was mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100 to 1:1000 and allowed to react at room temperature for 4 h; 3) Add 600 μL of the walking nucleic acid chain obtained in step 1) and 600 μL of the hairpin nucleic acid chain H1 obtained in step 2) at a molar ratio of 1:5-1:10 to 18 mL of magnetic core-gold shell nanoparticles to form a mixture, and react at room temperature overnight; 4) Add 28 mM thiol polyethylene glycol methoxy SH-PEG-OMe and magnetic core gold shell nanoparticles in a volume ratio of 1:100-1:1000 to the mixture prepared in step 3), react at room temperature for 10 min, centrifuge at 2000 rpm for 10 min for washing, and finally disperse the product in PBS buffer to prepare the Walker probe; (II) Preparation of the Second Reagent, i.e., SERS Probe 1) After the hairpin nucleic acid chain H2 is annealed, it is mixed with tricarboxyethylphosphine solution at a molar ratio of 1:100 to 1:1000 and reacted at room temperature for 4 hours; 2) Mix 10 μM hairpin nucleic acid chain H2 and gold nanoparticles at a volume ratio of 1:5-1:10 at room temperature overnight, and then add 2 M NaCl in small amounts several times within 4 hours to age the probe; 3) Add 100 μM Raman signal molecule 5,5'-dithiobis(2-nitrobenzoic acid) and gold nanoparticles at a volume ratio of 1:10-1:20 to the mixture obtained in step 2) and react for 3 hours; 4) Remove the supernatant by centrifugation, and disperse the centrifugal sediment with PBS solution to obtain the SERS probe; (III) Preparation of the third reagent: Dissolve zinc sulfate heptahydrate in ultrapure water to prepare a zinc sulfate solution that assists DNAzyme in specifically cleaving the substrate nucleic acid chain.
4. The non-diagnostic application of the ratiometric detection kit for circulating tumor cells according to claim 2 in the detection of circulating tumor cells MCF-7 in breast cancer, characterized in that: The application steps include: 1) Add MCF-7 cells to PBS buffer to obtain a sample solution for later use; wherein the concentration of MCF-7 cells in the obtained sample solution ranges from 5 to 1000 cells / mL; 2) mixing the first reagent, the second reagent, the third reagent and a sample solution containing different numbers of MCF-7 cells to be detected; 3) The mixed sample obtained in step 2) was magnetically separated and washed several times with PBS buffer and then subjected to SERS testing. The SERS spectra of different numbers of MCF-7 cells to be tested were detected, and 5,5'-dithiobis(2-nitrobenzoic acid), i.e., DTNB, was obtained at 1331 cm -1 Characteristic peak signal intensity I 1331 and ROX at 1500 cm -1 Characteristic peak signal intensity I 1500 The ratio I R =I 1331 / I 1500 , According to the working curve of the SERS detection kit, the detection limit of the SERS detection kit for detecting MCF-7 cells was calculated.
5. The non-diagnostic application of the ratiometric detection kit for circulating tumor cells according to claim 4 in the detection of circulating tumor cells MCF-7 of breast cancer, characterized in that: The co-culture condition in step 3) is to culture in a constant temperature mixer at 37° C. and 300 rpm for 60 minutes.
6. The non-diagnostic application of the ratiometric detection kit for circulating tumor cells according to claim 5 in the detection of circulating tumor cells MCF-7 of breast cancer, characterized in that: The applying step also includes, MCF-7 cells were added to the peripheral blood extract sample to obtain a sample solution for use, wherein the concentration range of MCF-7 cells in the obtained sample solution was 75-600 cells / mL; the first reagent, the second reagent, and the third reagent were mixed with the sample solution containing different numbers of MCF-7 cells to be detected; the mixed sample obtained by the above treatment was magnetically separated and washed for multiple times with PBS buffer, and then a SERS test was performed to obtain a SERS spectrum, and a DTNB at 1331 cm -1 Characteristic peak signal intensity I 1331 and ROX at 1500 cm -1 Characteristic peak signal intensity I 1500 The ratio I R =I 1331 / I 1500 According to the working curve of the SERS detection kit in the PBS buffer sample, the concentration of circulating tumor cells in the simulated clinical samples was calculated, and the practical performance of the detection kit was characterized.
7. A non-diagnostic application of the ratiometric detection kit for circulating tumor cells according to any one of claims 4 to 6 in the detection of circulating tumor cells MCF-7 in breast cancer, characterized in that: In the step 2), the first reagent, the second reagent and the third reagent are mixed with a sample solution containing different numbers of MCF-7 cells to be detected at a volume ratio of 1:0.2:1 to 1:2:
1.
8. The non-diagnostic application of the ratiometric detection kit for circulating tumor cells according to claim 7 in the detection of circulating tumor cells MCF-7 of breast cancer, characterized in that: The base sequence of the nucleic acid aptamer SYL3C-ROX chain is shown in SEQ ID NO.1, the Zn 2+ The base sequence of the specific DNAzyme chain is shown in SEQ ID NO.2, the base sequence of the hairpin nucleic acid chain H1 is shown in SEQ ID NO.3, and the base sequence of the hairpin nucleic acid chain H2 is shown in SEQ ID NO.4.
